Blastic Plasmacytoid Dendritic Cell Neoplasm: Management After First-Line Therapy Has Not Achieved Response

Clinical Scenario

This protocol addresses patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) whose disease did not achieve the expected response to first-line treatment, or who relapsed after initial therapy.

First-Line Failure Condition

First-line therapy — tagraxofusp (SL-401) or intensive chemotherapy (HCVAD, 7+3, or CHOP) — was expected to produce normalization of peripheral blood counts, bone marrow blasts below 5%, regression of nodal, spleen, and liver masses, and complete clearance of all skin lesions with no new lesions. When these goals are not reached, escalation to a subsequent treatment line is indicated.

Next-Line Approach (Partial Overview)

For relapsed or refractory BPDCN, management involves lower-intensity options or agents targeting specific cellular pathways — including a bcl-2 inhibitor used alone or in combination. The complete sequence of options, preferred agents, and combinations is detailed in the full protocol.

Full regimen details, combination strategies, and sequencing are available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

Some other lower-intensity options that have been used to treat BPDCN include gemcitabine and docetaxel, azacitidine, pralatrexate, and bendamustine.

Venetoclax, a bcl-2 inhibitor has been used as monotherapy and in combination with intensive chemotherapy (HCVAD) and hypomethylating agents in small series.

DOI: 10.6004/jnccn.2023.7026

View source ↗